Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.

Patients with relapsed/refractory multiple myeloma (RRMM) presents a therapeutic challenge. Among the diverse combinations of therapeutic agents, lenalidomide plus low-dose dexamethasone (Len-dex) therapy is a standard of care for RRMM.[1][1] However, since RRMM patients tend to progress despite